Charles Mallo

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

Part of Seelos Therapeutics, Inc., Scomedica SASU is a pharmaceutical company based in Montigny-le-Bretonneux, France. The French company manufactures pharmaceutical products. Scomedica was acquired by Apricus Biosciences, Inc. from Finesco, Inc. on July 13, 2012 for $11.16 million.

Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas.

Founded in 2015, EUSA Pharma Holdco 1 (UK) Ltd. is a holding British company that operates subsidiaries which wholesale pharmaceutical products. The company is based in Hempstead, UK.

EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom.

Part of Medtronic Plc, CardioRhythm is a company that manufactures electrophysiological catheters. The company is based in San Jose, CA. CardioRhythm was acquired by Medtronic, Inc., part of Medtronic Plc from January 27, 2015 on May 26, 1992.

Sierra Ventures, Inc (Sierra Ventures) is a venture capital firm founded in 1982 by Peter Wendell. The firm is headquartered in San Mateo, California.

Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.

White Pine Medical, Inc. manufactures and markets medical devices. The company was founded in February 2010 and is headquartered in Park City, UT.

Heartport, Inc. develops systems and procedures for heart surgery. The company's technologies allow surgeons to perform a wide range of less invasive open-chest and minimally invasive heart operations, including stopped heart and beating heart procedures. Heartport was founded in 1991 and is headquartered in Redwood City, CA.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

IPVALUE Management, Inc. provides strategic intellectual property consultation services. It specializes in IP rights licensing, technology transfer and enablement, spin-outs, and new venture formation. The company was founded by Peter Wheeler and Joseph J. Cote in 2001 and is headquartered in Santa Clara, CA.